1- Marchesini G. et al, Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome. Hepatology 2003;37:917-923
2- Matthew J. Armstrong MJ. Et al, Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort Original Research Article Journal of Hepatology, Volume 56, Issue 1, January 2012, Pages 234-240
3- Ratziu V. et al Gastroentérologie Clinique et Biologique. Vol 33 - N° 8-9 P. 850-858 - août 2009
4- Ekstedt M. et al Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology. 2006 Oct;44(4):865-73
5- Gastaldelli A. et al, Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133:496-506, 2007)
6- Schindhelm RK. Et al, Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191:391–396
7- Tiikkainen M. et al, Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003 Mar;52(3):701-7.
8- Katsutaro Morino K, Petersen KF. Et al, Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction Diabetes December 2006 55:S9-S15
9- Musso G. et al, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010 Jul;52(1):79-104.
10- Sanyal AJ.et al, Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis N Engl J Med 2010; 362:1675-1685
Cas clinique
Le prurigo nodulaire
Étude et pratique
HTA : quelle PA cible chez les patients à haut risque cardiovasculaire ?
Mise au point
Troubles psychiatriques : quand évoquer une maladie neurodégénérative ?
Étude et pratique
Complications de FA, l’insuffisance cardiaque plus fréquente que l’AVC